There’s more to MIF

How MIF, sCD74 could prevent or treat AKI after cardiac surgery

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac surgery patients, contributing to emerging evidence that targeting MIF’s protective activity is therapeutically tractable.

MIF is known to interact with multiple receptors, including CXC chemokine receptor 2 (CXCR2; IL8RB), CXCR4 (NPY3R) and co-receptor CD44, to promote or prevent inflammation. Most commercial interest

Read the full 768 word article

User Sign In